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1352Objective: Themammalian target of rapamycin signaling pathwayhasbeen implicated in therapeutic resistance in
several types of cancer.However, the significance ofmammalian target of rapamycin activation in chemoradiother-
apy sensitivity and its effect on the prognosis of esophageal squamous cell carcinoma treatedwith chemoradiother-
apy remain unknown. However, this pathway is of particular interest because an effective inhibitor is available.
Methods:By using immunohistochemistry, phosphorylated mammalian target of rapamycin expression was ex-
amined in 77 patients with esophageal squamous cell carcinoma treated with preoperative chemoradiotherapy
followed by surgery between 1999 and 2009, and correlated with treatment outcome. With the use of CE81T/
VGH and TE2 cell lines, cells were treated with chemotherapy, temsirolimus (mammalian target of rapamycin
inhibitor), or a combination of chemotherapy and temsirolimus, and investigated by 3-(4.5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide assay.
Results: Pathologic complete response rates were 42% and 16% in patients with negative and positive phos-
phorylated mammalian target of rapamycin expression, respectively (P ¼ .01). The 3-year overall survivals
were 57% and 30% in patients with negative and positive phosphorylated mammalian target of rapamycin ex-
pression, respectively (P ¼ .005). Positive phosphorylated mammalian target of rapamycin expression was in-
dependently associated with inferior overall and disease-free survival. In patients who did not achieve pathologic
complete response, postchemoradiotherapy esophagectomy specimens showed significantly higher phosphory-
lated mammalian target of rapamycin expression than pretreatment biopsy specimens. In cell lines, concomitant
administration of temsirolimus enhanced the effect of chemotherapy.
Conclusions: Phosphorylated mammalian target of rapamycin expression is independently associated with the
response to chemoradiotherapy and prognosis of patients with esophageal squamous cell carcinoma treated with
preoperative chemoradiotherapy. Mammalian target of rapamycin inhibition can sensitize esophageal cancer
cells to chemotherapy. Our results suggest the potential for mammalian target of rapamycin as a therapeutic
target for patients with esophageal squamous cell carcinoma who receive multimodality treatment. (J Thorac
Cardiovasc Surg 2012;144:1352-9)Supplemental material is available online.
The outcome of patientswith advanced esophageal squamous
cell carcinoma (ESCC) treated with surgery alone is unsatis-
factory.1,2 In an attempt to improve survival, a multimodality
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However, the value of the surgery after chemoradiotherapy
remains unclear. Recent phase III trials3,4 showed that
surgery may not be necessary for those patients who
respond well to chemoradiotherapy. After preoperative
chemoradiotherapy, pathologic complete response is found
in only 20% to 40% of patients3-6 and is associated with
improved survival.7 However, there is still a large portion ofFunding: This work was supported in part by grants from the National Science
Council, Taiwan (NSC 100-2314-B-182A-044-MY3) and Chang Gung Memorial
Hospital (CMRPG890631).
Disclosures: Authors have nothing to disclose with regard to commercial support.
Received for publicationMarch 10, 2012; revisions receivedMay 18, 2012; accepted
for publication June 18, 2012; available ahead of print July 27, 2012.
Address for reprints: Chang-Han Chen, PhD, Kaohsiung Chang Gung Esophageal
Cancer Group, Cancer Center, and Center for Translational Research in Biomed-
ical Sciences, Kaohsiung Chang Gung Memorial Hospital and Chang Gung Uni-
versity College of Medicine, 123 Ta-Pei Rd, Niaosung Hsiang, Kaohsiung Hsien,
Taiwan, ROC (E-mail: chench7@gmail.com).
0022-5223/$36.00
Copyright  2012 by The American Association for Thoracic Surgery
http://dx.doi.org/10.1016/j.jtcvs.2012.06.049
gery c December 2012
Abbreviations and Acronyms
AJCC ¼ American Joint Committee on Cancer
CDI ¼ combination drug index
CI ¼ confidence interval
CT ¼ computed tomography
DFS ¼ disease-free survival
DMEM ¼ Dulbecco’s Modified Eagle Medium
ESCC ¼ esophageal squamous cell carcinoma
EUS ¼ endoscopic ultrasound
5-FU ¼ 5-fluorouracil
mTOR ¼ mammalian target of rapamycin
OR ¼ odds ratio
OS ¼ overall survival
p-mTOR ¼ phosphorylated mammalian target of
rapamycin
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Spatients who do not respond well to chemoradiotherapy. In
addition, there are substantial differences in the response to
chemoradiotherapy and survival between patients with the
same clinical stage. Therefore, there is an urgent need to iden-
tify patients who are likely to respond to chemoradiotherapy
to spare them the potential perioperative morbidity and mor-
tality. A reliable marker that can precisely predict the tumor
response to chemoradiotherapy in patients with ESCC is im-
portant, and this marker may serve as a therapeutic target in
the future.
The mammalian target of rapamycin (mTOR), also
known as ‘‘FK506 binding protein 12-rapamycin associated
protein 1,’’ is a serine/threonine protein kinase that plays
a key role in regulating protein synthesis, ribosomal protein
translation, and cap-dependent translation.8 Deregulation in
mTOR signaling is frequently associated with tumorigene-
sis, angiogenesis, tumor growth, and metastasis.8 In re-
sponse to extracellular stimuli, mTOR is activated by
phosphorylation of Ser2448 through the phosphatidylinosi-
tol 3-kinase/AKT signaling pathway.8 Activation of mTOR
stimulates the phosphorylation of 2 key downstream pro-
teins that regulate protein translation: eukaryotic initiation
factor 4E binding protein-1 and protein S6 kinase 1.
Through the activation of eukaryotic initiation factor 4E
and protein S6 kinase 1, mTORC complex 1 promotes the
translation of messenger RNAs that often encode proteins
necessary for cell cycle progression, cell growth, and me-
tabolism. A number of studies suggest that activation of
the mTOR signaling pathway plays an important role in
multiple anticancer drug–resistance mechanisms in several
types of cancer.9 In particular, a recent development of the
mTOR inhibitor temsirolimus has generated considerable
excitement in both the clinical and the basic cancer research
communities, because it exhibits potent activity against
a wide panel of cancers.10 Therefore, further elucidationThe Journal of Thoracic and Carof the mTOR activation in human cancers is critical for an-
ticancer therapy targeting the mTOR signaling pathway.
However, the significance of mTOR activation in chemora-
diotherapy sensitivity and its effect on the prognosis of pa-
tients with ESCC treated with chemoradiotherapy remain
unclear.
Thus, we evaluated the mTOR activity with immunohis-
tochemistry and investigated the prognostic role of mTOR
activation in 77 patients with ESCC who were treated
with preoperative chemoradiotherapy followed by surgery.
In addition, we also use ESCC cell lines to determine
whether the mTOR inhibitor can enhance the effect of
chemotherapy.MATERIALS AND METHODS
Patient Population
Patients with ESCCwhowere treated with chemoradiotherapy at Kaoh-
siung Chang Gung Memorial Hospital between January 1999 and Decem-
ber 2009 were retrospectively reviewed. This study was approved by the
institutional review board of Chang Gung Memorial Hospital. All patients
selected for this study were required to undergo esophagectomy after che-
moradiotherapy to allow pathologic correlation.
During this period, 109 patients with ESCC who were treated with
preoperative chemoradiotherapy followed by surgery were identified.
Among these 109 patients, 25 (23%) achieved pathologic complete re-
sponse. Pretreatment specimens of biopsy were available in 77 patients.
Patients were evaluated by a multidisciplinary team, including a thoracic
surgeon, medical oncologist, radiation oncologist, radiologist, and gastro-
enterologist. Pretreatment staging evaluation included physical examina-
tion, endoscope, contrast-enhanced computed tomography (CT) scans
from the neck to upper abdomen, and endoscopic ultrasound (EUS).
All 77 patients had CT scans. EUS was performed in 61 patients. In pa-
tients who did not receive EUS, T stage was determined by CT scans
only. The clinical staging was determined according to the American
Joint Committee on Cancer (AJCC) staging system (AJCC Cancer
Staging Manual, 7th Edition).11
Treatment Plan
Patients were treated with 2 cycles of cisplatin and 5-fluorouracil
(5-FU)–based chemotherapy and radiotherapy (36 Gy in 20 fractions)
concurrently. The interval between treatment cycles was 3 to 4 weeks.
Radiotherapy of 1.8 Gy per day was delivered 5 days per week for 4
weeks. Three-dimensional conformal radiotherapy via a 4-field technique
was used in most cases. Within 3 to 4 weeks after the end of irradiation,
a CT scan was performed to assess the treatment response. The multidis-
ciplinary team reviewed the clinical information to determine whether the
lesions were resectable. If yes, surgery was advised approximately 4 to 6
weeks after the end of preoperative chemoradiotherapy. Patients undergo-
ing surgery had a radical esophagectomy with cervical esophagogastric
anastomosis (McKeown procedure) or an Ivor Lewis esophagectomy
with intrathoracic anastomosis, reconstruction of the digestive tract with
gastric tube, and pylorus drainage procedures. Two-field lymph node dis-
section was performed in all patients. Pathologic complete response was
defined as the complete disappearance of all viable cancer cells in all sur-
gical specimens, including the primary esophageal tumor and lymph
nodes.
Patient Follow-up
After the operation, patients were scheduled for follow-ups at 3-month
intervals in years 1 and 2, 6-month intervals in years 3 to 5, and annuallydiovascular Surgery c Volume 144, Number 6 1353
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Sthereafter. Overall survival (OS) was calculated from the date of diagnosis
to death as a result of all causes. Disease-free survival (DFS) was computed
from the time of surgery to the recurrence or death from any cause without
evidence of recurrence.
Immunohistochemistry
Immunohistochemistry staining was performed using an immunoperox-
idase technique. Staining was performed on slides (4 mm) of formalin-
fixed, paraffin-embedded tissue sections with primary antibodies against
phosphorylated mTOR (p-mTOR) (Ser2448, Clone 49F9, 1:50, Cell Sig-
naling Technology, Inc, Danvers, Mass). Briefly, after deparaffinization
and rehydration, the retrieval of the antigen was performed by treating
the slides in 10 mmol/L citrate buffer (pH 6.0) in a hot water bath
(95C) for 20 minutes. Endogenous peroxidase activity was blocked for
15 minutes in 0.3% hydrogen peroxide. After blocking with 1% goat se-
rum for 1 hour at room temperature, the sections were incubated with pri-
mary antibodies for at least 18 hours at 4C overnight. Immunodetection
was performed using the LSAB2 kit (Dako, Carpinteria, Calif) followed
by 3-3’-diaminobenzidine for color development and hematoxylin for
counterstaining. Incubation without the primary antibody and normal
esophageal squamous epithelium12 were used as a negative control. A nor-
mal gastric gland12 was used as a positive control. The staining assessment
was independently carried out by 2 pathologists (S.L.W. and W.T.H) with-
out any information about clinicopathologic features or prognosis. The
fraction of tumor cells with cytoplasmic p-mTOR expression (0%-
100%) was recorded, and the average value of 2 pathologists was calcu-
lated in each patient. Whenever the 2 pathologists disagreed (eg, difference
>10% or discordant scores), the slides were reevaluated and discussed, and
a consensus was reached by 2 pathologists. Then p-mTOR expression level
was scored by using the 3-tier system: negative expression (score 0), less
than 10%; low expression (score 1), 10% or more, but less than 50%;
and high expression (score 2), 50% or more tumor cells with staining.13,14
When scores were classified into 2 groups for statistical analysis, ‘‘low’’
and ‘‘high’’ were combined as ‘‘positive.’’12-14Cell Culture and 3-(4.5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide Assay
Human esophageal cancer cells (CE81T/VGH), a cell line derived
from a well-differentiated squamous cell carcinoma of the esophagus,
were provided by Dr C-C Yen (Taipei Veterans General Hospital, Taipei,
Taiwan) and cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal calf serum, 2 mmol/L glutamine, 100 U/
mL penicillin, and 100 ig/mL streptomycin. Human esophageal cancer
cells (TE2), a cell line derived from a poorly differentiated squamous
cell carcinoma of the esophagus, were provided by Dr W-C Huang
(Mackay Memorial Hospital, Taipei, Taiwan) and cultured in DMEM
supplemented with 10% fetal calf serum, 2 mmol/L glutamine, 100 U/
mL penicillin, and 100 ig/mL streptomycin. The rapamycin analogue
CCI-779 (temsirolimus) was provided by Wyeth-Ayerst (King of
Prussia, Pa).
To test the effects of cell proliferation of chemotherapy alone and in
combination with temsirolimus on cell proliferation, cells were plated
into 96-well, flat-bottomed plates at 3 3 103 cells per 100 mL per well in
DMEM containing 10% fetal bovine serum. After overnight incubation,
triplicate wells were treated with chemotherapy alone, temsirolimus alone,
or chemotherapy in combination with different concentrations of temsiro-
limus for 24 hours. The relative percentages of metabolically active
cells compared with untreated controls were then determined on the
basis of mitochondrial conversion of 3-(4.5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide to formazine. In brief, after incubation,
10 mL of 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(Sigma, St Louis, Mo) solution (5 mg/mL) was added to each well for 3
hours, and then the medium was replaced with 150 mL of dimethyl1354 The Journal of Thoracic and Cardiovascular Sursulfoxide per well. Results were assessed in a 96-well format plate reader
by measuring the absorbance at a wavelength of 540 nm using a Titertek
Multiscan (Thermo, Finland).Statistical Analysis
For patient data, statistical analysis was performed using the Statisti-
cal Package for the Social Sciences 17 software package (SPSS Inc, Chi-
cago, Ill). The chi-square and Fisher exact tests were used to compare
data between the 2 groups. Changes in p-mTOR expression during che-
moradiotherapy were analyzed by the McNemar–Bowker test. Multivar-
iate analysis of pathologic complete response was performed by logistic
regression, and variables with P values less than .1 identified at the uni-
variate level were entered into the model. For survival analysis, the Ka-
plan–Meier method was used for univariate analysis, and the difference
between survival curves was tested by a log-rank test. In a stepwise for-
ward fashion, parameters with P values less than .1 at the univariate level
were entered into the Cox regression model to analyze their relative prog-
nostic importance. For all analyses, 2-sided tests of significance were
used.
For ESCC cell line experiments, t test was used for the statistical anal-
ysis. Data are presented as means  standard deviation. Each experiment
was carried out independently at least twice, with 3 repeats each. The com-
bination drug index (CDI) was used to evaluate whether the combination of
drug A and drug B was synergistic or not, which was calculated according
to the following formula15: CDI ¼ survival% (drug Aþdrug B)/survival
% (drug A) 3 survival % (drug B). The value of CDI less than 1 meant
synergistic drug interaction.RESULTS
Patient Characteristics
A total of 77 patients were collected in the study with
a median age of 52 years (range, 37-77 years). Among
them, 75 were men and 2 were women. The pretreatment
analyses of the clinical tumor stage revealed T2 in 4 patients
(5%), T3 in 39 patients (51%), and T4 in 34 patients
(44%). Additional pretreatment analyses according to the
AJCC staging system demonstrated clinical stage II tumors
for 16 patients (21%) and clinical stage III for 61 patients
(79%). Further analyses of histologic grades showed a grade
1 lesion in 12 patients, grade 2 in 44 patients, and grade 3 in
21 patients. Primary tumor location was found to be upper
in 13 patients (17%), middle in 38 patients (49%), and
lower in 26 patients (34%).
Among these 77 patients, 21 achieved pathologic com-
plete response after preoperative chemoradiotherapy. The
3-year OS and DFS for these 77 patients were 42% and
38%, respectively. The median periods of follow-up
were 73.2 months (range, 28.6-120 months) for the 24
survivors and 22.6 months (range, 3.8-120 months) for
all 77 patients.Correlation Between Clinicopathologic Parameters
and Expression of Phosphorylated Mammalian
Target of Rapamycin
p-mTOR immunoreactivity was absent in normal squa-
mous cell epithelium (Figure 1, A) but was present in nor-
mal gastric glands (Figure 1, B). Among the 77 patientsgery c December 2012
FIGURE 1. Immunohistochemical staining of p-mTOR. A, p-mTOR immunoreactivity was absent in normal squamous cell epithelium (black arrows).
Original magnification 3200. B, p-mTOR immunoreactivity was present in normal gastric glands (black arrows). Original magnification 3400. C, Rep-
resentative example of negative p-mTOR expression in ESCC. Original magnification3100. D, Representative example of positive p-mTOR expression in
ESCC. Original magnification 3100.
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pression and 44 (57%) showed ‘‘positive’’ for p-mTOR
(Figure 1,C andD). p-mTOR expression was not associated
with any clinicopathologic parameters, including age,
gender, primary tumor location, histologic grade, keratiniz-
ing, AJCC staging, T staging, and N staging (data not
shown).
Correlation Between Clinicopathologic Parameters
and Pathologic Complete Response
The relationship between the clinicopathologic parame-
ters and the response to chemoradiotherapy is summarized
in Table 1. Negative p-mTOR expression (P ¼ .01) was sig-
nificantly associatedwith pathologic complete response after
chemoradiotherapy. The pathologic complete response rate
was 42% in patients with negative p-mTOR expression
compared with 16% in patients with positive p-mTOR
expression. The logistic model showed that negative
p-mTOR expression (P ¼ .012; odds ratio [OR], 3.891;
95% confidence interval [CI], 1.346-11.236) independently
correlated with pathologic complete response after
chemoradiotherapy.
Survival Analyses
Correlations of clinicopathologic parameters and p-mTOR
expressionwithOS andDFS are summarized in Table 2. Uni-
variate analyses demonstrated that positive p-mTOR expres-
sion (3-yearOS rate, 30%vs57%,P¼ .005; 3-yearDFS rate,The Journal of Thoracic and Car25% vs 54%, P ¼ .015; Figure 2, A and B), AJCC stage III
(3-year OS rate, 34% vs 68%, P ¼ .015; 3-year DFS rate,
30% vs 68%, P ¼ .007), T4 disease (3-year OS rate, 27%
vs 54%, P ¼ .01; 3-year DFS rate, 24% vs 49%,
P ¼ .007), and positive regional lymph nodes (3-year OS
rate, 33% vs 61%, P ¼ .019; 3-year DFS rate, 28% vs
61%, P ¼ .005) were associated with the inferior OS and
DFS. In multivariate comparison, positive p-mTOR expres-
sion (OS, P ¼ .001; OR, 2.814; 95% CI, 1.553-5.097; DFS,
P ¼ .003; OR, 2.438; 95% CI, 1.368-4.347), T4 disease
(OS, P ¼ .005; OR, 2.256; 95% CI, 1.276-3.990; DFS,
P¼ .005; OR, 2.227; 95% CI, 1.271-3.902), and positive re-
gional lymph nodes (OS, P ¼ .015; OR, 2.329, 95% CI,
1.180-4.598; DFS, P ¼ .003; OR, 2.749; 95% CI, 1.399-
5.402) represented independent adverse prognosticators for
OS and DFS. The 3-year OS and DFS were 30% and 25%,
respectively, in patients with positive p-mTOR expression,
and 57% and 54%, respectively, in patients with negative
p-mTOR expression.
Change of the Phosphorylated Mammalian Target of
Rapamycin Expression After Chemoradiotherapy
Among the 77 patients collected, 56 did not achieve
pathologic complete response after chemoradiotherapy.
Immunohistochemical p-mTOR expression scores were
compared between the biopsy samples obtained before
chemoradiotherapy and the esophagectomy specimens
after chemoradiotherapy. Esophagectomy specimens afterdiovascular Surgery c Volume 144, Number 6 1355




Absent Present P value
Age
<52 y 25 11 .54
52 y 31 10
AJCC stage
II 9 7 .12
III 47 14
T stage
T2þ3 28 15 .092
T4 28 6
N stage
N0 14 9 .127
N1þ2þ3 42 12
Tumor grade
1þ2 38 18 .12
3 18 3
Primary tumor location
Upper/middle 38 13 .62
Lower 18 8
Keratinizing
Absent 11 4 1.00
Present 45 17
p-mTOR
<10% 19 14 .01*
10% 37 7
AJCC, American Joint Committee on Cancer; p-mTOR, phosphorylated mammalian
target of rapamycin. *Statistically significant. Chi-square or Fisher exact test was
used for statistical analysis.
TABLE 2. Results of univariate log-rank analysis of prognostic factors
for overall and disease-free survivals in 77 patients with esophageal















<52 y 36 44 .51 39 .66
52 y 41 39 37
p-mTOR
<10% 33 57 .005* 54 .015*
10% 44 30 25
AJCC stage
II 16 68 .015* 68 .007*
III 61 34 30
T classification
T2þ3 43 54 .01* 49 .007*
T4 34 27 24
N status
N0 23 61 .019* 61 .005*
N1þ2þ3 54 33 28
Tumor grade
1 12 58 .35 58 .34
2þ3 65 38 34
Primary tumor location
Upper/middle 51 39 .48 35 .49
Lower 26 46 42
Keratinizing
Absent 15 33 .44 27 .47
Present 62 44 40
Pathologic CR
Absent 56 30 .009* 25 .007*
Present 21 71 71
OS, Overall survival; DFS, disease-free survival; p-mTOR, phosphorylated mamma-
lian target of rapamycin; AJCC, American Joint Committee on Cancer; CR, complete
General Thoracic Surgery Li et al
G
T
Schemoradiotherapy showed significantly (P ¼ .004,
Figure 2, C) higher percentages of high p-mTOR scores
than the biopsy samples before chemoradiotherapy.response. *Statistically significant.Mammalian Target of Rapamycin Inhibitor
Potentiates Growth Inhibition by Chemotherapy in
Esophageal Squamous Cell Carcinoma Cell Lines
Our clinical data showed that p-mTOR expression is
significantly associated with the response to chemoradio-
therapy. Therefore, we tested whether the mTOR inhibi-
tor temsirolimus can potentiate growth inhibition by
chemotherapy in ESCC cell lines, CE81T/VGH and
TE2. We compared the ability of the mTOR inhibitor
temsirolimus to exhibit cooperative effects with cisplatin
or 5-FU using doses of chemotherapy that resulted in ap-
proximately 15% to 30% growth inhibition when given
alone. Temsirolimus alone displayed a growth-inhibitory
effect in a dose-dependent manner (Figure E1). In addi-
tion, a combination of chemotherapy and temsirolimus
showed significantly better growth inhibition than chemo-
therapy or temsirolimus alone (Figure 3). Synergistic ef-
fects were also observed, especially in TE2 ESCC cell
lines.1356 The Journal of Thoracic and Cardiovascular SurDISCUSSION
Previous studies have revealed that mTOR activation
is associated with poor prognosis in numerous human
cancers.16,17 However, the significance of mTOR activation
in chemoradiotherapy sensitivity and its effect on the
prognosis of patients with ESCC treated with chemoradio-
therapy remain unknown. Thus, we focused on the patients
with ESCC who were treated with preoperative chemoradio-
therapy and undertook the present study to determine the
significance of mTOR activation in chemoradiotherapy
sensitivity and patients’ survival.
In the present study, a significant inverse correlation be-
tween expression of p-mTOR and the response to chemo-
radiotherapy was found. A total of 14 (42%) of 33
patients with negative p-mTOR expression achieved path-
ologic complete response after preoperative chemoradio-
therapy, but only 7 (16%) of 44 patients with positive
p-mTOR expression achieved pathologic completegery c December 2012
FIGURE 2. A, OS according to p-mTOR status. B, DFS according to p-mTOR status. C, Percentage of high p-mTOR scores was significantly higher in the
esophagectomy specimens after chemoradiotherapy compared with biopsy specimens before chemoradiotherapy (P ¼ .004, left). Representative paired
samples of a biopsy specimen (middle, p-mTOR score¼ 0, original magnification340) and an esophagectomy specimen (right, p-mTOR score¼ 2, original
magnification 3100). p-mTOR, Phosphorylated mammalian target of rapamycin; CRT, chemoradiotherapy.
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usually diagnosed at an advanced stage. The use of preop-
erative chemoradiotherapy followed by surgery or defini-
tive chemoradiotherapy has been increasing in recent
years for patients with advanced ESCC. After chemora-
diotherapy, no viable tumors are observed in 20% to
40% of resected esophageal tumor specimens. The thera-
peutic long-term benefit to achieve a pathologic complete
response is suggested with multiple retrospective series
reporting 5-year survivals of 40% to 60% in those groups
of patients compared with those with specimens contain-
ing residual disease.7 On the other hand, perioperative
morbidity and mortality may be increased by preoperative
chemoradiotherapy.18 The ability to identify patients who
cannot respond well to chemoradiotherapy may allow
more appropriate selection of multimodality treatment
options.The Journal of Thoracic and CarIn our study, a significantly higher p-mTOR expression
was found in the specimens obtained after the postchemor-
adiotherapy esophagectomy than the specimens collected
before treatment. Previous studies report that mTOR
activation after anticancer therapy plays an important
role in protecting cells from undergoing apoptosis.9,19
Beuvink and colleagues20 recently reported that the
inhibition of mTOR activation sensitized tumor cells to
cisplatin-induced apoptosis through p53-induced p21 ex-
pression. Furthermore, the activation ofmTOR after chemo-
radiotherapy in ESCC may also be involved in the
stimulation of glycolysis. Warburg21 observed that cancer
cells prefer glycolytic pathways with lactic acid fermenta-
tion in the cytosol to aerobic respiratory activity with mito-
chondrial oxidation of pyruvate for energy generation. This
metabolic switch renders cancer cells less dependent on an
oxygen supply and may allow them to survive in a morediovascular Surgery c Volume 144, Number 6 1357
FIGURE 3. A and B, Temsirolimus inhibits cell growth in combination with cisplatin in CE81Tand TE2 ESCC cell lines. CE81Tand TE2 ESCC cell lines
were treated with cisplatin alone, temsirolimus alone, or a combination of cisplatin and temsirolimus. Cisplatin was given at a single concentration. C and D,
Temsirolimus inhibits cell growth in combination with 5-FU. CE81Tand TE2 ESCC cell lines were treated with 5-FU alone, temsirolimus alone, or a com-
bination of 5-FU and temsirolimus. 5-FU was given at a single concentration. *Significant difference in growth inhibition after combination treatment
compared with chemotherapy or temsirolimus alone. Columns, mean; bars, standard deviation. 5-FU, 5-Fluorouracil; S, synergistic effect; Tem, temsiro-
limus.
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therapy or radiotherapy. This phenomenon may contribute
to the resistance to chemotherapy and radiotherapy. Recent
studies demonstrated that mTOR activation is critical for the
metabolic switch to aerobic glycolysis of cancer cells.22
The mTOR inhibitor has been approved for clinical use in
the systemic treatment of advanced renal cell carcinoma.9,10
Several preclinical studies have also suggested that the
mTOR inhibitor can enhance the efficacy of a variety of
chemotherapeutic agents in breast,23 ovarian,24 and colon25
cancers. However, little is known about the combination ef-
fect of the mTOR inhibitor and cytotoxic agents in ESCC.
Hou and colleagues26 reported that the mTOR inhibitor ra-
pamycin significantly inhibits the growth of ESCC when
combined with cisplatin. In the present study, we found
that the mTOR inhibitor temsirolimus enhances the effect
of cisplatin and 5-FU, which are common chemotherapeutic
agents used in ESCC. These results indicate that the mTOR
inhibitor can enhance the potentiation of conventional che-
motherapy and serve as a new therapeutic tool for patients
with advanced ESCC.1358 The Journal of Thoracic and Cardiovascular SurStudy Limitations
Our study has important limitations. Most of the patients
in this study did not have fluorine 18 fluorodeoxyglucose
positron emission tomography scans during pretreatment
staging or in restaging after neoadjuvant chemoradiother-
apy because 18 fluorodeoxyglucose-positron emission to-
mography scans are not routinely supported by Taiwan’s
health insurance. Furthermore, our observations were also
limited by relatively short follow-up periods and small
patient numbers.CONCLUSIONS
Our study showed that p-mTOR expression is indepen-
dently associated with the response to chemoradiotherapy
and prognosis of patients with ESCC who were treated
with preoperative chemoradiotherapy. Furthermore, inhibi-
tion of mTOR can sensitize esophageal cancer cells to che-
motherapy. Therefore, mTOR may be a target for
therapeutic intervention in patients with ESCC who receive
multimodality treatment.gery c December 2012
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FIGURE E1. Temsirolimus alone displayed a growth-inhibitory effect in a dose-dependent manner in 2 ESCC cell lines: CE81T (A) and TE2 (B).
*Significant difference in growth inhibition. Columns, mean; bars, standard deviation.
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